The Role of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer

被引：13
作者：
Seshadri R.A. [1 ]
Glehen O. [2 ,3 ]
机构：
[1] Department of Surgical Oncology, Cancer Institute (WIA), Chennai
[2] Department of Surgical oncology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre-Bénite Cedex
[3] Université Lyon 1, EMR 3738, Oullins
来源：
Indian Journal of Surgical Oncology | 2016年 / 7卷 / 2期
关键词：
Cytoreductive surgery; Gastric cancer; Hyperthermic intraperitoneal chemotherapy; Peritoneal carcinomatosis;
D O I：
10.1007/s13193-016-0502-8
中图分类号：
学科分类号：
摘要：
Peritoneal metastasis, either synchronous or metachronous, is commonly seen in gastric cancer. It is associated with a poor prognosis, with a median survival of less than one year. The outcomes are not significantly improved by the use of systemic chemotherapy. We review the relevant literature on the role of HIPEC in gastric cancer. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been used in three situations in gastric cancer. Besides its role as a definitive treatment in patients with established peritoneal metastasis (PM), it has been used as a prophylaxis against peritoneal recurrence after curative surgery and also as a palliative treatment in advanced peritoneal metastasis with intractable ascites. While prophylactic HIPEC has been shown to reduce peritoneal recurrence and improve survival in many randomised trials, palliative HIPEC can reduce the need for frequent paracentesis. Although CRS with HIPEC has shown promise in increasing the survival of selected patients with established PM from gastric cancer, larger studies are needed before this can be accepted as a standard of care. © 2016, Indian Association of Surgical Oncology.
引用
收藏
页码：198 / 207
页数：9
相关论文
共 79 条
  • [1] Abbasi S.Y., Taani H.E., Saad A., Badheeb A., Addasi A., Advanced gastric cancer in Jordan from 2004 to 2008: a study of epidemiology and outcomes, Gastrointest Cancer Res, 4, pp. 122-127, (2011)
  • [2] Thomassen I., van Gestel Y.R., van Ramshorst B., Luyer M.D., Bosscha K., Nienhuijs S.W., Lemmens V.E., de Hingh I.H., Peritoneal carcinomatosis of gastric origin: A population-based study on incidence, survival and risk factors, Int J Cancer, 134, pp. 622-628, (2014)
  • [3] Sasako M., Sano T., Yamamoto S., Kurokawa Y., Nashimoto A., Kurita A., Hiratsuka M., Tsujinaka T., Kinoshita T., Arai K., Yamamura Y., Okajima K., Group J.C.O., D2 lymphadenectomy alone or with Para-aortic Nodal Dissection for Gastric Cancer, N Engl J Med, 359, pp. 453-462, (2008)
  • [4] Spolverato G., Ejaz A., Kim Y., Squires M.H., Poultsides G.A., Fields R.C., Schmidt C., Weber S.M., Votanopoulos K., Maithel S.K., Pawlik T.M., Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis, J Am Coll Surg, 219, pp. 664-675, (2014)
  • [5] Roviello F., Marrelli D., de Manzoni G., Morgagni P., Di Leo A., Saragoni L., De Stefano A on behalf of the Italian Research Group for Gastric Cancer. Prospective study of peritoneal recurrence after curative surgery for gastric cancer, Br J Surg, 90, pp. 1113-1119, (2003)
  • [6] Wu C.W., Lo S.S., Shen K.H., Hsieh M.C., Chen J.H., Chiang J.H., Lin H.J., Li A.F., Lui W.Y., Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer, World J Surg, 27, pp. 153-158, (2003)
  • [7] Sakuramoto S., Sasako M., Yamaguchi T., Kinoshita T., Fujii M., Nashimoto A., Furukawa H., Nakajima T., Ohashi Y., Imamura H., Higashino M., Yamamura Y., Kurita A, and Arai K for the ACTS-GC Group Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine, N Engl J Med, 357, pp. 1810-1820, (2007)
  • [8] Bang Y.J., Kim Y.W., Yang H.K., Chung H.C., Park Y.K., Lee K.H., Lee K.W., Kim Y.H., Noh S.I., Cho J.Y., Mok Y.J., Kim Y.H., Ji J., Yeh T.S., Button P., Sirzen F., Sh N., CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial, Lancet, 28, (2012)
  • [9] Cunningham D., Allum W.H., Stenning S.P., Thompson J.N., Van de Velde C.J., Nicolson M., Scarffe J.H., Lofts F.J., Falk S.J., Iveson T.J., Smith D.B., Langley R.E., Verma M., Weeden S., Chua Y.J., MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer, N Engl J Med, 355, pp. 11-20, (2006)
  • [10] Smalley S.R., Benedetti J.K., Haller D.G., Hundahl S.A., Estes N.C., Ajani J.A., Gunderson L.L., Goldman B., Martenson J.A., Jessup J.M., Stemmermann G.N., Blanke C.D., Macdonald J.S., Updated analysis of SWOG-directed intergroup Study 0116:A phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection, J Clin Oncol, 30, pp. 2327-2333, (2012)
12345678